165 related articles for article (PubMed ID: 32499442)
1. MTOR signaling orchestrates stress-induced mutagenesis, facilitating adaptive evolution in cancer.
Cipponi A; Goode DL; Bedo J; McCabe MJ; Pajic M; Croucher DR; Rajal AG; Junankar SR; Saunders DN; Lobachevsky P; Papenfuss AT; Nessem D; Nobis M; Warren SC; Timpson P; Cowley M; Vargas AC; Qiu MR; Generali DG; Keerthikumar S; Nguyen U; Corcoran NM; Long GV; Blay JY; Thomas DM
Science; 2020 Jun; 368(6495):1127-1131. PubMed ID: 32499442
[TBL] [Abstract][Full Text] [Related]
2. mTOR Signaling Confers Resistance to Targeted Cancer Drugs.
Guri Y; Hall MN
Trends Cancer; 2016 Nov; 2(11):688-697. PubMed ID: 28741507
[TBL] [Abstract][Full Text] [Related]
3. The evolution of the TOR pathway and its role in cancer.
Beauchamp EM; Platanias LC
Oncogene; 2013 Aug; 32(34):3923-32. PubMed ID: 23246968
[TBL] [Abstract][Full Text] [Related]
4. mTOR: Role in cancer, metastasis and drug resistance.
Murugan AK
Semin Cancer Biol; 2019 Dec; 59():92-111. PubMed ID: 31408724
[TBL] [Abstract][Full Text] [Related]
5. Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells.
Chiarini F; Evangelisti C; Lattanzi G; McCubrey JA; Martelli AM
Biochim Biophys Acta Mol Cell Res; 2019 Aug; 1866(8):1322-1337. PubMed ID: 30928610
[TBL] [Abstract][Full Text] [Related]
6. Targeting PI3K in cancer: mechanisms and advances in clinical trials.
Yang J; Nie J; Ma X; Wei Y; Peng Y; Wei X
Mol Cancer; 2019 Feb; 18(1):26. PubMed ID: 30782187
[TBL] [Abstract][Full Text] [Related]
7. Targeting mTOR for cancer therapy.
Hua H; Kong Q; Zhang H; Wang J; Luo T; Jiang Y
J Hematol Oncol; 2019 Jul; 12(1):71. PubMed ID: 31277692
[TBL] [Abstract][Full Text] [Related]
8. Long noncoding RNAs in the mTOR signaling network: biomarkers and therapeutic targets.
Huang T; Wang M; Huang B; Chang A; Liu F; Zhang Y; Jiang B
Apoptosis; 2018 Jun; 23(5-6):255-264. PubMed ID: 29556906
[TBL] [Abstract][Full Text] [Related]
9. Multi-targeted kinase inhibition alleviates mTOR inhibitor resistance in triple-negative breast cancer.
He J; McLaughlin RP; van der Noord V; Foekens JA; Martens JWM; van Westen G; Zhang Y; van de Water B
Breast Cancer Res Treat; 2019 Nov; 178(2):263-274. PubMed ID: 31388935
[TBL] [Abstract][Full Text] [Related]
10. AMPK and Cancer.
Wang Z; Wang N; Liu P; Xie X
Exp Suppl; 2016; 107():203-226. PubMed ID: 27812982
[TBL] [Abstract][Full Text] [Related]
11. The role of RICTOR downstream of receptor tyrosine kinase in cancers.
Jebali A; Dumaz N
Mol Cancer; 2018 Feb; 17(1):39. PubMed ID: 29455662
[TBL] [Abstract][Full Text] [Related]
12. Targeted Inhibition of Rictor/mTORC2 in Cancer Treatment: A New Era after Rapamycin.
Zou Z; Chen J; Yang J; Bai X
Curr Cancer Drug Targets; 2016; 16(4):288-304. PubMed ID: 26563881
[TBL] [Abstract][Full Text] [Related]
13. [mTOR complexes -- molecular spiders in molecular networks].
Kopper L; Tímár J
Magy Onkol; 2011 Nov; 55(4):287-94. PubMed ID: 22128312
[TBL] [Abstract][Full Text] [Related]
14. Ciclopirox olamine inhibits mTORC1 signaling by activation of AMPK.
Zhou H; Shang C; Wang M; Shen T; Kong L; Yu C; Ye Z; Luo Y; Liu L; Li Y; Huang S
Biochem Pharmacol; 2016 Sep; 116():39-50. PubMed ID: 27396756
[TBL] [Abstract][Full Text] [Related]
15. Mechanisms of resistance against cancer therapeutic drugs.
Chatterjee S; Damle SG; Sharma AK
Curr Pharm Biotechnol; 2014; 15(12):1105-12. PubMed ID: 25429651
[TBL] [Abstract][Full Text] [Related]
16. Enigmas in tumor resistance to kinase inhibitors and calculation of the drug resistance index for cancer (DRIC).
Smith CIE
Semin Cancer Biol; 2017 Aug; 45():36-49. PubMed ID: 27865897
[TBL] [Abstract][Full Text] [Related]
17. Targeting autophagy to overcome drug resistance in cancer therapy.
Kumar A; Singh UK; Chaudhary A
Future Med Chem; 2015 Aug; 7(12):1535-42. PubMed ID: 26334206
[TBL] [Abstract][Full Text] [Related]
18. Revisiting mTOR inhibitors as anticancer agents.
Teng QX; Ashar YV; Gupta P; Gadee E; Fan YF; Reznik SE; Wurpel JND; Chen ZS
Drug Discov Today; 2019 Oct; 24(10):2086-2095. PubMed ID: 31173912
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways.
McCubrey JA; Steelman LS; Kempf CR; Chappell WH; Abrams SL; Stivala F; Malaponte G; Nicoletti F; Libra M; Bäsecke J; Maksimovic-Ivanic D; Mijatovic S; Montalto G; Cervello M; Cocco L; Martelli AM
J Cell Physiol; 2011 Nov; 226(11):2762-81. PubMed ID: 21302297
[TBL] [Abstract][Full Text] [Related]
20. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]